King of Prussia District Logo
  • News
  • Blog
  • Events
  • Contact
  • Explore King of Prussia
    • Hotels, Conference & Meeting Spaces
      Hotels, Conference & Meeting Spaces
    • Fun & Fitness
      Fun & Fitness
    • Shopping
      Shopping
    • Dining & Nightlife
      people eating dinner and cheers with beer glasses
      Dining & Nightlife
    • Parks & Trails
      Parks & Trails
    • Healthcare & Life Sciences
      Healthcare & Life Sciences
    • Getting Around
      bus driver sitting in bus
      Getting Around
    • Small Business Directory
      open sign hanging in a window
      Small Business Directory
  • Development
    • Future Plans
      artistic rendering of exteriors of multiple buildings
      Future Plans
    • Recently Completed
      exterior of topgolf building
      Recently Completed
    • Development Map
      image of a map on a laptop screen
      Development Map
  • Do Business
    • HQ KOP
      HQ KOP
    • Business Parks
      Business Parks
    • Available Commercial Space
      office building rendering
      Available Commercial Space
    • Job Opportunities
      people working in an office
      Job Opportunities
    • Research & Data Analytics
      Research & Data Analytics
  • Live
    • Housing
      apartment living room
      Housing
    • Education
      Education
    • Community Resources
      family with shopping carts full of food
      Community Resources
  • Recently Completed
  • Future Plans
  • What We Do
    • About Us
      aerial view of King of Prussia
      About Us
    • District Opportunities & Updates
      District Opportunities & Updates
    • Resources & Publications
      mock up of Annual Report to the Community
      Resources & Publications
    • Stakeholder Meetings
      desk with electronic devices and office supplies on it
      Stakeholder Meetings
  • Sponsorships
  • linkedin-in-brands
  • instagram-brands
Contact
Sponsorships
August 30, 2017

CSL Behring acquires Tucson biotech for $91 million

  • Facebook Icon
  • Twitter Icon
  • LinkedIn Icon

Source, philly.com, Linda Lloyd

Biotherapeutics company CSL Behring in King of Prussia will buy Calimmune Inc. for at least $91 million to add an early-stage stem-cell gene therapy for sickle-cell disease to its product pipeline.

The Tucson-based biotechnology firm is working on a gene therapy and has two “platform” technologies to address challenges in the manufacturing and administration of gene- and stem-cell-based treatments, aligning with CSL Behring’s expertise in hematology.

In addition to the $91 million, the agreement includes performance-based milestone payments of up to $325 million. The deal is expected to close within two weeks.

Calimmune, a private company, has about 40 employees and research and drug-development facilities in Pasadena, Calif., and Sydney, Australia.

Calimmune’s “Select+” and “Cytegrity” technologies are “designed to address some of the major challenges currently associated with the commercialization of stem-cell therapy,” according to CSL Behring. This includes the ability to manufacture consistent, high-quality products, and to improve engraftment, efficacy, and tolerability, the company said in a statement. “Both technologies have broad applications in ex-vivo stem-cell gene therapy.”

This type of treatment involves genetically altering cells outside the body before transplanting them back into the patient.

Currently, patients with sickle-cell disease receive chemotherapy to knock out bad cells in bone marrow to make room for good, new cells, said CSL Behring spokeswoman Natalie de Vane. But patients can become very ill, and administering the treatment requires a hospital visit.

Calimmune’s “Select+” technology would potentially allow lower doses of chemotherapy by reducing toxicity and improving efficacy of the gene therapy. The hope is that patients would not become as sick, and the procedure could be handled in a doctor’s office instead of a hospital, she said.

CSL Behring, which employs about 700 in King of Prussia, makes products to treat bleeding disorders such as hemophilia and immune deficiency diseases.

CSL Behring is part of CSL Limited in Melbourne, Australia. CSL chief executive officer and managing partner Paul Perreault said: “Calimmune shares in our promise and focus to improve the lives of patients with rare and serious medical conditions. The acquisition represents another important step in the execution of our strategy for sustainable growth. Calimmune’s scientific accomplishments are impressive.”

While Calimmune is still in the early stages, “we believe that our combined strengths have tremendous potential to change treatment paradigms, and most importantly, significantly improve the lives of our patients,” Perreault said.

Calimmune’s chief executive officer, Louis Breton, said: “We are excited to become part of CSL Behring. They are an established global industry leader in protein-replacement therapies and have a proven track record. …  Together, we are well-positioned to take our achievements to the next level.”

 

Related Posts

View All
Aug 28, 2025 News

Fully leased office campus near King of Prussia Mall sells for $68M

The Philadelphia Inquirer
Aug 26, 2025 News

Here’s when Netflix House in King of Prussia will open

Fox29
Aug 26, 2025 District News

Investing in the Future: UMASD by the Numbers

Read More
Aug 25, 2025 News

The world’s first Netflix House is opening in King of Prussia this fall

The Philadelphia Inquirer
Aug 25, 2025 News

Netflix House to open at King of Prussia Mall on Nov. 12

Philly Voice
Aug 25, 2025 News

Netflix House Sets Opening Dates For Philadelphia & Dallas Entertainment Venues

Deadline
Aug 25, 2025 News

Netflix House Opening Dates Revealed for Philadelphia and Dallas Locations

The Hollywood Reporter
Aug 25, 2025 News

The world’s first Netflix House is opening in King of Prussia this fall

The Philadelphia Inquirer
Aug 25, 2025 News

First Netflix House opens its doors on November 12th

The Verge
Aug 25, 2025 News

Netflix Sets Opening Dates for Permanent Entertainment and Shopping Venues in Philadelphia, Dallas

Variety

Keep Up With KOP

Be the first to hear about new events and experiences.
Subscribe Now
  • Explore
  • Do Business
  • Live
  • Get Around
  • Development
  • What We Do
  • 2025 Sponsors
  • linkedin-in-brands
  • instagram-brands
©2025 King of Prussia District All Rights Reserved
Privacy Policy
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset
  • SitemapSitemap